Fedora Pharmaceuticals: FPI-2119 Lactivicin-Class Antibiotic Shows Potent Bactericidal Activity at ESCMID 2026
Fedora Pharmaceuticals presented eight posters at ESCMID Global 2026 in Munich today highlighting FPI-2119, a first-in-kind derivative of the lactivicin class for Gram-negative infections. As a non-β-lactam antibiotic, FPI-2119 is not susceptible to β-lactamases. Posters demonstrated concentration-dependent bactericidal activity and low resistance frequency against Pseudomonas aeruginosa, maintained activity against β-lactamase-expressing E. coli strains, and activity against resistant Campylobacter, Salmonella, and Shigella.